000 02201nas a22002535i 4500
001 3120-421X
003 DE-He213
005 20260304140725.0
007 cr nn 008mamaa
008 251031s||||||||xxkuu poo|||||| b|EN |d
022 _a3120-421X
024 7 _a44560
_2local
210 1 0 _aNat. Prog. Oncol.
245 1 0 _aNature Progress Oncology
_h[electronic resource] /
_cedited by Nathalie Le Bot.
264 1 _aLondon :
_bNature Publishing Group UK :
_bImprint: Nature Portfolio.
300 _bonline resource.
520 _aDraft: Nature Progress Oncology focuses on advancing scientific knowledge and clinical practice in the field of oncology and carcinogenesis While the journal will welcome original research and translational studies that contribute to understanding the prevention, mechanisms, diagnosis, and treatment of cancer, the journal will also encourage interdisciplinary submissions that bridge basic science and clinical application. The journal will also publish clinical trials phases I-III within oncology. Key areas of interest include, but are not limited to: Cancer Cell Biology: cellular mechanisms, metastasis and cancer stem cells. Cancer Immunology: tumour microenvironment, immunomodulation Cancer Genetics and Genomics: genetic mutations, epigenetics, genomic instability Pre-clinical Cancer Models: in vitro systems, in vivo models and translational relevance Cancer Therapy Development: immunotherapies, targeted therapies, combination treatments, therapy resistance Cancer Diagnosis and Detection: liquid biopsies, imaging innovations, biomarkers, pathology, early detection Molecular Targets and Pathways: identification and validation of molecular pathways, drug discovery Technological Innovations in Cancer: AI and machine learning, computational oncology Cancer Epidemiology: cancer incidence, risk factors, health disparities, socio-economic impacts.
650 0 _aCancer.
650 1 4 _aCancer Biology.
700 1 _aLe Bot, Nathalie.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_916034
710 2 _aSpringerLink (Online service)
856 4 0 _uhttps://www.nature.com/natprogoncology
_zOpen Access
999 _c579948
_d579948